Trial Profile

A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-19 vaccine-OSE Immunotherapeutics (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man; Pharmacodynamics
Acronyms COVEPIT-3
Sponsors OSE Immunotherapeutics

Most Recent Events

16 Mar 2022 Positive results published in an OSE Immunotherapeutics Media Release.
30 Nov 2021 According to an OSE Immunotherapeutics media release, 6-month immunogenicity results on the long-term memory T response are anticipated in the first quarter of 2022.
30 Nov 2021 Interim results presented in an OSE Immunotherapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com